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GenotypeEven in the era of new oral anticoagulants (NOACs) for
prevention of thromboembolisms in patients with atrial ﬁbrilla-
tion (AF), the traditional oral anticoagulant—warfarin—has not lost
its importance in various clinical settings. Warfarin is indispens-
able for patients with mechanical valves, deep vein thrombosis,
pulmonary embolism, and intracardiac thrombus. In addition,
some of the patients with AF prefer warfarin over NOACs because
of its affordability. Warfarin is also recommended for patients with
renal impairment who need anticoagulant therapy because
warfarin is metabolized by the liver and not directly excreted
through the kidney. On the other hand, NOACs are excreted by the
kidney and may accumulate in patients with renal impairment
leading to an increased risk of hemorrhagic events. Therefore, at
the present, NOACs are not available in Japan for patients with
severe renal impairment.
Renal function and its impact on warfarin therapy
Before prescription of NOACs, it is mandatory for clinicians to
evaluate renal function (i.e. estimated creatinine clearance (eCrCl)
and/or estimated glomerular ﬁltration rate (eGFR)) to prevent
hemorrhagic complications. The clinicians have to determine
whether to adjust the dose or stop the use of NOACs based on the
evaluation of renal function. On the other hand, during warfarin
therapy, we usually do not pay much attention to the renal
function of the patients. Warfarin has been typically prescribed
and managed similarly in patients with severe renal impairment
and even patients undergoing hemodialysis [1,2]. Renal im-
pairment, however, has been recognized not only as a risk factor
of thromboembolic events, but also as a risk of hemorrhagic
complications during warfarin therapy [1–4]. HAS-BLED score,
which has been developed for patients with AF to evaluate
bleeding risk, incorporates abnormal renal function as one of the
risk factors [5]. Regarding the pathophysiological mechanisms of
the increased risk of hemorrhage in patients with renalDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.08.008
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have been reported [2].
In this issue of the journal, Ichihara et al. [6] investigated the
effect of impaired renal function on the maintenance dose of
warfarin and provided insight into the increased risk of hemorrhagic
events in patients with renal impairment. The important ﬁndings to
be emphasized are that there is a signiﬁcant correlation between
warfarin dose and estimated creatinine clearance, and patients with
moderate/severe renal impairment have a lower maintenance dose
of warfarin than those with no/mild renal impairment in Japanese
population. Similar ﬁndings have been also conﬁrmed in recent
studies consisting of African- and European-American patients
[7,8]. Considering the genetic, demographic, and clinical differences,
which greatly inﬂuence dose response of warfarin [9], the ﬁndings
reported by Ichihara et al. would be valuable in the real clinical
practice in this country. They discussed that renal impairment can
signiﬁcantly reduce nonrenal clearance and alter the bioavailability
of drugs predominantly metabolized by the liver, which would
result in lower warfarin dosages [10].
Limdi et al. [7,8] reported that patients with severe renal
impairment (eGFR <30 ml/min/1.73 kg/m2) required signiﬁcantly
lower warfarin dosages. In addition, they conﬁrmed that patients
with severe renal impairment were at a signiﬁcantly higher risk for
over-anticoagulation (prothrombin time/international normalized
ratio (PT-INR) >4) and had a higher incidence of major hemorrhage
compared with patients with no/mild or moderate renal im-
pairment [7]. Hylek et al. [11] reported that the risk for
hemorrhagic events was particularly increased during the ﬁrst
30–90 days after initiation of warfarin, because the initial dose
often results in PT-INR of >3.0. Although hemorrhagic complica-
tions are not always related to a high intensity of anticoagulation,
the target intensity of anticoagulation and especially the actual
achieved intensity have been recognized as major determinants of
anticoagulation-related hemorrhages [12,13]. These observations
suggest that we should deﬁnitely evaluate renal function for
patients who are due to receive warfarin therapy; for patients with
renal impairment, warfarin should be initiated at a lower dosage
and more closely monitored to prevent over-anticoagulation and
hemorrhagic events.
Estimation of maintenance dose of warfarin
The narrow therapeutic index of warfarin and the wide
interindividual variability make the estimation of appropriate
dosage challenging. In the current clinical practice, warfarin isss under CC BY-NC-ND license.
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mean maintenance dose of warfarin reported by Ichihara et al. [6]
was 3.54  1.44 mg/day for patients with eGFR 60 ml/min/1.73 m2,
2.88  1.42 mg/day for eGFR of 30 to <60 ml/min/1.73 m2, and
2.33  1.04 mg/day for eGFR of <30 ml/min/1.73 m2. These data are
helpful to plan the initiation dose of warfarin especially for patients
with renal impairment in this country, although stable doses to
achieve a target INR usually vary widely.
The second ﬁnding to be emphasized from Ichihara et al. [6] is
the more accurate formula for predicting warfarin maintenance
dose, compared with the previously proposed formula which does
not incorporate renal function. The formula from Ichihara
et al. includes eCrCl as well as the other following parameters:
age, body weight, VKORC1-1639 G>A genotype, and target PT-INR.
The coefﬁcient of determination (r2) of this formula is 0.47, which
means that this formula accurately predicts the maintenance dose
and may lead to shorter time required to achieve the optimal
control of PT-INR and reduce the period of over- and under-
anticoagulation state.
Two genes, VKORC1 and CYP2C9, have been identiﬁed to be
associated with variation in warfarin maintenance dose [9]. In this
study, variant in CYP2C9 was rare and the genotype was not
incorporated into the formula from Ichihara et al. The clinical
utility of genotype-guided dosing of warfarin has been tested in
two randomized trials; however, the utility is still controversial
[14,15]. To arrive at a deﬁnite conclusion on whether the genotype-
guided dosing of warfarin is useful or not, we need to wait for the
results of other randomized trials, especially in the Japanese
population.
In conclusion, as Ichihara et al. and other researchers indicated,
renal function greatly affects the metabolism of warfarin. We have
to pay more attention to renal function before we initiate or
continue warfarin therapy as in the case of NOACs.
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